Last reviewed · How we verify
Chemotherapy plus monoclonal antibody
Chemotherapy plus monoclonal antibody works by targeting cancer cells with a combination of chemotherapy agents and monoclonal antibodies that specifically bind to and destroy cancer cells.
Chemotherapy plus monoclonal antibody works by targeting cancer cells with a combination of chemotherapy agents and monoclonal antibodies that specifically bind to and destroy cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic colorectal cancer.
At a glance
| Generic name | Chemotherapy plus monoclonal antibody |
|---|---|
| Also known as | Standard CHemotherapy plus monoclonal antibody |
| Sponsor | Grupo Espanol Multidisciplinario del Cancer Digestivo |
| Drug class | Chemotherapy plus monoclonal antibody |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Chemotherapy agents in this combination work by interfering with the growth and replication of cancer cells, while monoclonal antibodies target specific proteins on the surface of cancer cells, marking them for destruction. This dual approach can be more effective than chemotherapy alone in treating certain types of cancer.
Approved indications
- Metastatic non-small cell lung cancer, PD-L1 positive
- Metastatic colorectal cancer
Common side effects
- Neutropenia
- Fatigue
- Nausea
- Diarrhea
- Anemia
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: